Market Overview

Benzinga's Top Upgrades

Related BMY
UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates
#PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets
Apple Leads the Charge as Earnings Season Heats Up (Fox Business)
Related GNRC
Fast Money Halftime Report Final Trade From October 3: Generac Holdings Inc., Bank of America Corp
Fast Money Picks For August 14
Home Improvement Stocks Tumble (Fox Business)

Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday.

Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC) from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday.

Guggenheim Securities upgraded FMC Technologies (NYSE: FTI) from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday.

Analysts at Bank of America upgraded Astrazeneca PLC (NYSE: AZN) from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2014BMO CapitalUpgradesMarket PerformOutperform
Oct 2014JefferiesMaintainsHold
Oct 2014Guggenheim SecuritiesInitiates Coverage onNeutral

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (AZN + BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters